News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Image-Guided Neurologics and Peregrine Pharmaceuticals Agree to Study Use Of Navigus(R) Array Catheter in Treatment of Brain Cancer (PR Newswire) Image-Guided Neurologics, a medical device company developing access and navigational products for minimally invasive neurosurgery techniques, and Peregrine Pharmaceuticals, Inc., have agreed to co-sponsor a Phase I/II pilot study for Cotara(TM), Peregrine`s Tumor Necrosis Therapy drug, that utilizes IGN`s Navigus(R) Array multi-lumen intracranial catheter in patients with brain cancer. - Aug 22 7:45 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/prnews/010822/mnw004_2.html

Posted on: 08/22/2001

"Yahoo - Image-Guided Neurologics and Peregrine Pharmaceuticals Agree to Study Use Of Navigus(R) Array Catheter in Treatment of Brain Cancer"
Yahoo! Finance Finance Home - Yahoo! - Help
PR Newswire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
PPHM
1.65
+0.01
delayed 20 mins - disclaimer

Wednesday August 22, 7:45 am Eastern Time

Press Release

SOURCE: Image-Guided Neurologics, Inc.

Image-Guided Neurologics and Peregrine Pharmaceuticals Agree to Study Use Of Navigus(R) Array Catheter in Treatment of Brain Cancer

New Catheter May Enhance Delivery of Targeted Cancer Therapy

MELBOURNE, Fla., Aug. 22 /PRNewswire/ --

Image-Guided Neurologics (IGN), a medical device company developing access and navigational products for minimally invasive neurosurgery techniques, and Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - news), have agreed to co-sponsor a Phase I/II pilot study for Cotara(TM), Peregrine's Tumor Necrosis Therapy drug, that utilizes IGN's Navigus® Array multi-lumen intracranial catheter in patients with brain cancer.

Cotara is a radiolabeled monoclonal antibody that targets the necrotic core of tumors and uses beta-radiation to kill the tumors from the inside out. Unlike traditional treatments, such as chemotherapy, pre-clinical studies have shown Cotara grows more effective with successive use as the region of necrosis, or dying cells, grows in size. Since necrotic tissue is common to all tumors, Cotara may have broad application across all tumor types.

The Navigus Array Catheter, available in a variety of sizes and configurations, is designed to optimize the delivery of drugs and cells to targeted sites within the brain through a series of independent microcatheters that extend from a host catheter. Its proprietary multi-lumen approach allows for multiple drug infusion approaches via a single entry point. The catheter has 510(k) approval from the U.S. Food and Drug Administration and is commercially available in the United States and Europe.

The pilot study is designed to further characterize the flow and distribution characteristics of the Array catheter when used with Cotara, as well as to better understand methods to improve overall distribution of the drug at the tumor site. Approximately six patients will be enrolled in the pilot study at the Medical University of South Carolina.

"We are pleased that Peregrine Pharmaceuticals has selected IGN's Navigus Array Catheter for use with Cotara," said Rudy Mazzocchi, IGN president and CEO. "IGN seeks to offer the Array catheter to neurosurgeons involved in various clinical trials exploring the exciting frontiers of neurosurgical drug and cell therapy. We are developing applications for a wide range of neurological conditions, including brain cancer, stroke, and neurodegenerative disorders, such as essential tremor, Parkinson's disease and epilepsy."

Sunil Patel, M.D., associate professor of neurosurgery at the Medical University of South Carolina and principal investigator for the study, said, "For other patients in the Phase I/II Cotara study, we have used standard ventricular and peritoneal catheters to deliver Cotara directly to the site of the malignant brain tumor. After studying the Array catheter's unique design and functionality, I selected it for this study with the goal of improving infusion and distribution of the drug."

"We are pleased to collaborate with IGN and Dr. Patel in studying the array catheter with Cotara in a clinical setting," said Edward Legere, Peregrine's president and CEO. "Our ultimate goal is to perfect the infusion methods of Cotara in brain cancer in order to capture all of the cancerous tissue within the 'kill zone' of the radioisotope. If we can capture all of the cancerous tissue within the 'kill zone,' we have a much better chance of giving a patient a complete remission. The array catheter appears to give neurosurgeons more control and flexibility in infusing Cotara in brain cancer. This study will not change our plans to open a multi-center Phase III brain cancer study later this year."

Peregrine Pharmaceuticals, based in Tustin, Calif., is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The company has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA) and Vascular Targeting Agents (VTA). To learn more about Peregrine, visit their web site at http://www.peregrineinc.com

IGN, a privately held company, is a leading innovator in the development of access and navigational products for less invasive neurosurgical techniques. The company is developing and commercializing products that are designed to enable frameless stereotaxy and improve the speed with which these procedures can be performed. IGN's products include the Navigus® Trajectory Guidance Systems, which are FDA-approved and available commercially in the United States and Europe. To learn more about Image-Guided Neurologics and their products, visit the company's Web site at http://www.igneurologics.com

SOURCE: Image-Guided Neurologics, Inc.

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Peregrine Pharmaceuticals Inc (NasdaqSC:PPHM - news)
Related News Categories: biotech, education, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740